ArcGIS. Johns Hopkins University. Retrieved 30 June 2020.
Cui, S., Chen, S., Li, X., Liu, S., and Wang, F. (2020). Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J. Thromb. Haemost.
Dal Moro, F., and Livi, U. (2020). Any possible role of phosphodiesterase type 5 inhibitors in the treatment of severe COVID19 infections? A lesson from urology. Clin. Immunol. 214 : 108414.
Dallan, C., Romano, F., Siebert, J., Politi, S., Lacroix, L., and Sahyoun, C. (2020). Septic shock presentation in adolescents with COVID-19. Lancet Child Adolesc. Heal.
Dastan, F., Nadji, S.A., Saffaei, A., and Tabarsi, P. (2020). Tocilizumab administration in a refractory case of COVID-19. Int. J. Antimicrob. Agents 106043 :.
Didangelos, A. (2020). Neutrophil involvement in Covid-19. Preprints.
Driggin, E., Madhavan, M. V., Bikdeli, B., Chuich, T., Laracy, J., Biondi-Zoccai, G., et al. (2020). Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic. J. Am. Coll. Cardiol. 75 : 2352–2371.
Dunkern, T.R., Feurstein, D., Rossi, G.A., Sabatini, F., and Hatzelmann, A. (2007). Inhibition of TGF-β induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activators of soluble guanylyl cyclase. Eur. J. Pharmacol. 572 : 12–22.
Dunne, A.E., Kawamatawong, T., Fenwick, P.S., Davies, C.M., Tullett, H., Barnes, P.J., et al. (2019). Direct Inhibitory Effect of the PDE4 Inhibitor Roflumilast on Neutrophil Migration in Chronic Obstructive Pulmonary Disease. Am. J. Respir. Cell Mol. Biol. 60 : 445–453.
Dusser, D.J., Djokic, T.D., Borson, D.B., and Nadel, J.A. (1989). Cigarette smoke induces bronchoconstrictor hyperresponsiveness to substance P and inactivates airway neutral endopeptidase in the guinea pig. Possible role of free radicals. J. Clin. Invest. 84 : 900–906.
El-Sayed, N.S., and Bayan, Y. (2015). Possible role of Resveratrol targeting Estradiol and Neprilysin pathways in Lipopolysaccharide model of Alzheimer disease. Adv. Exp. Med. Biol. 822 : 107–118.
Elshazly, M., Hosny, H., Abdel-Hafiz, H., Zakaria, A., Elkaffas, K., and Okasha, N. (2013). Assessment of endothelial dysfunction in idiopathic pulmonary fibrosis. Egypt. J. Chest Dis. Tuberc. 62 : 589–592.
Feng, H., Chen, J., Wang, H., Cheng, Y., Zou, Z., Zhong, Q., et al. (2017). Roflumilast reverses polymicrobial sepsis-induced liver damage by inhibiting inflammation in mice. Lab. Investig. 97 : 1008–1019.
Fertig, Bracy A., and G.S.B. (2018). PDE4-Mediated cAMP Signalling. J. Cardiovasc. Dev. Dis. 5 : 8.
Fitzgerald, M.F., Spicer, D., McAulay, A.E., Wollin, L., and Beume, R. (2006). Roflumilast but not methylprednisolone inhibited cigarette smoke-induced pulmonary inflammation in guinea pigs. Eur. Respir. J. Suppl.
Franceschi, C., Garagnani, P., Parini, P., Giuliani, C., and Santoro, A. (2018). Inflammaging: a new immune–metabolic viewpoint for age-related diseases. Nat. Rev. Endocrinol. 14 : 576–590.
Fu, B., Xu, X., and Wei, H. (2020). Why tocilizumab could be an effective treatment for severe COVID-19? J. Transl. Med. 18 : 164.
Fuchs, T.A., Brill, A., Duerschmied, D., Schatzberg, D., Monestier, M., Myers, D.D.J., et al. (2010). Extracellular DNA traps promote thrombosis. Proc. Natl. Acad. Sci. U. S. A. 107 : 15880–15885.
Fukakusa, M., Bergeron, C., Tulic, M.K., Fiset, P.O., Dewachi, O. Al, Laviolette, M., et al. (2005). Oral corticosteroids decrease eosinophil and CC chemokine expression but increase neutrophil, IL-8, and IFN-γ-inducible protein 10 expression in asthmatic airway mucosa. J. Allergy Clin. Immunol. 115 : 280–286.
Funakoshi, Y., Ichiki, T., Ito, K., and Takeshita, A. (1999). Induction of interleukin-6 expression by angiotensin II in rat vascular smooth muscle cells. Hypertension 34 : 118–125.
Gauvreau, G.M., Boulet, L.P., Schmid-Wirlitsch, C., Côté, J., Duong, M.L., Killian, K.J., et al. (2011). Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects. Respir. Res.12 : 140.
Gentile, F., Raptis, A., Knipling, L.G., and Wolff, J. (1988). Extracellular cAMP formation from host cell ATP by Bordetella pertussis adenylate cyclase. BBA - Mol. Cell Res. 971 : 63–71.
George, P.M., Wells, A.U., and Jenkins, R.G. (2020). Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Respir. Med.
Gérard, A., Romani, S., Fresse, A., Viard, D., Parassol, N., Granvuillemin, A., et al. (2020). “Off-label” use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers. Therapies.
Gernez, Y., Tirouvanziam, R., and Chanez, P. (2010). Neutrophils in chronic inflammatory airway diseases: Can we target them and how? Eur. Respir. J. 35 : 467–469.
Ghasemi, H. (2018). Roles of IL-6 in Ocular Inflammation: A Review. Ocul. Immunol. Inflamm. 26 : 37–50.
Graf, K., Kunkel, K., Zhang, M., Gräfe, M., Schultz, K., Schudt, C., et al. (1995). Activation of adenylate cyclase and phosphodiesterase inhibition enhance neutral endopeptidase activity in human endothelial cells. Peptides 16 : 1273–1278.
Growcott, E.J., Spink, K.G., Ren, X., Afzal, S., Banner, K.H., and Wharton, J. (2006). Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells. Respir. Res. 7 :.
Gupta, P., and O’Mahony, M.S. (2008). Potential adverse effects of bronchodilators in the treatment of airways obstruction in older people: Recommendations for prescribing. Drugs and Aging 25 : 415–443.
Halpin, D.M.G. (2008). ABCD of the phosphodiesterase family: interaction and differential activity in COPD. Int. J. Chron. Obstruct. Pulmon. Dis.3 : 543–561.
Hamming, I., Timens, W., Bulthuis, M.L.C., Lely, A.T., Navis, G.J., and Goor, H. van (2004). Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol. 203 : 631–637.
Harding, S.D., Sharman, J.L., Faccenda, E., Southan, C., Pawson, A.J., Ireland, S., et al. (2018). The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY. Nucleic Acids Res. 46 : 1091–1106.
Hatzelmann, A., Morcillo, E.J., Lungarella, G., Adnot, S., Sanjar, S., Beume, R., et al. (2010). The preclinical pharmacology of roflumilast–a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther. 23 : 235–256.
He, J., Hu, L., Huang, X., Wang, C., Zhang, Z., Wang, Y., et al. (2020). Potential of coronavirus 3C-like protease inhibitors for the development of new anti-SARS-CoV-2 drugs: Insights from structures of protease and inhibitors. Int. J. Antimicrob. Agents 106055.
Henkin, R.I., Schmidt, L., and Velicu, I. (2013). Interleukin 6 in hyposmia. JAMA Otolaryngol. - Head Neck Surg. 139 : 728–734.
Hertz, A.L., Bender, A.T., Smith, K.C., Gilchrist, M., Amieux, P.S., Aderem, A., et al. (2009). Elevated cyclic AMP and PDE4 inhibition induce chemokine expression in human monocyte-derived macrophages. Proc. Natl. Acad. Sci. 106 : 21978–21983.
Hu, C., Lu, L., Wan, J.-P., and Wen, C. (2017). The Pharmacological Mechanisms and Therapeutic Activities of Hydroxychloroquine in Rheumatic and Related Diseases. Curr. Med. Chem. 24 : 2241–2249.
Hu, F., Jiang, J., and Yin, P. (2020). Prediction of potential commercially inhibitors against SARS-CoV-2 by multi-task deep model. ArXiv Prepr. 2003.00728 :
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., et al. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395 : 497–506.
Hung, M.J., Cherng, W.J., Hung, M.Y., Wu, H.T., and Pang, J.H.S. (2010). Interleukin-6 inhibits endothelial nitric oxide synthase activation and increases endothelial nitric oxide synthase binding to stabilized caveolin-1 in human vascular endothelial cells. J. Hypertens. 28 : 940–951.
Hyun, Y., and Hong, C. (2017). Deep insight into neutrophil trafficking in various organs. J. Leukoc. Biol. 102 : 617–629.
Insel, P.A., Murray, F., Yokoyama, U., Romano, S., Yun, H., Brown, L., et al. (2012). CAMP and Epac in the regulation of tissue fibrosis. Br. J. Pharmacol. 166 : 447–456.
Isoni, C.A., Borges, É.A., Veloso, C.A., Mattos, R.T., Chaves, M.M., and Nogueira-Machado, J.A. (2009). cAMP activates the generation of reactive oxygen species and inhibits the secretion of IL-6 in peripheral blood mononuclear cells from type 2 diabetic patients. Oxid. Med. Cell. Longev. 2 : 317–321.
Jacoby, D.B., Tamaoki, J., Borson, D.B., and Nadel, J.A. (1988). Influenza infection causes airway hyperresponsiveness by decreasing enkephalinase. J. Appl. Physiol. 64 : 2653–2658.
Jia, H. (2016). Pulmonary Angiotensin-Converting Enzyme 2 (ACE2) and Inflammatory Lung Disease. Shock 46 : 239–248.
Jin, J.-M., Bai, P., He, W., Wu, F., Liu, X.-F., Han, D.-M., et al. (2020). Gender Differences in Patients With COVID-19: Focus on Severity and Mortality. Front. Public Heal. 8 : 152.
Jones, N.A., Boswell-Smith, V., Lever, R., and Page, C.P. (2005). The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro. Pulm. Pharmacol. Ther. 18 : 93–101.
Joyce, E., Fabre, A., and Mahon, N. (2013). Hydroxychloroquine cardiotoxicity presenting as a rapidly evolving biventricular cardiomyopathy: Key diagnostic features and literature review. Eur. Hear. J. Acute Cardiovasc. Care 2 : 77–83.
Kassi, E., and Moutsatsou, P. (2010). Estrogen Receptor Signaling and Its Relationship to Cytokines in Systemic Lupus Erythematosus. J. Biomed. Biotechnol.
Kawamatawong, T. (2017). Roles of roflumilast, a selective phosphodiesterase 4 inhibitor, in airway diseases. J. Thorac. Dis.9 : 1144.
Kell, D.B., Heyden, E.L., and Pretorius, E. (2020). The Biology of Lactoferrin, an Iron-Binding Protein That Can Help Defend Against Viruses and Bacteria. Front. Immunol. 11 : 1221.
Kimball, A.S., Obi, A.T., Diaz, J.A., and Henke, P.K. (2016). The Emerging Role of NETs in Venous Thrombosis and Immunothrombosis. Front. Immunol. 7 : 236.
Kletsas, D., Caselgrandi, E., Barbieri, D., Stathakos, D., Franceschi, C., and Ottaviani, E. (1998). Neutral endopeptidase-24.11 (NEP) activity in human fibroblasts during development and ageing. Mech. Ageing Dev.102 : 15–23.
Klok, F.A., Kruip, M.J.H.A., Meer, N.J.M. van der, Arbous, M.S., Gommers, D.A.M.P.J., Kant, K.M., et al. (2020). Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb. Res.
Kowalczyk, A., Kleniewska, P., Kolodziejczyk, M., Skibska, B., and Goraca, A. (2015). The role of endothelin-1 and endothelin receptor antagonists in inflammatory response and sepsis. Arch. Immunol. Ther. Exp. (Warsz). 63 : 41–52.
Kuba, K., Imai, Y., Rao, S., Gao, H., Guo, F., Guan, B., et al. (2005). A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat. Med. 11 : 875–879.
Kumar, N., Goldminz, A.M., Kim, N., and Gottlieb, A.B. (2013). Phosphodiesterase 4-targeted treatments for autoimmune diseases. BMC Med. 11 : 96.
Kumar, R.K., Herbert, C., Thomas, P.S., Wollin, L., Beume, R., Yang, M., et al. (2003). Inhibition of inflammation and remodeling by roflumilast and dexamethasone in murine chronic asthma. J. Pharmacol. Exp. Ther.307 : 349–355.
Lai, C.C., Liu, Y.H., Wang, C.Y., Wang, Y.H., Hsueh, S.C., Yen, M.Y., et al. (2020). Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. J. Microbiol. Immunol. Infect. 53 : 404.
Leonard-Lorant, I., Delabranche, X., Severac, F., Helms, J., Pauzet, C., Collange, O., et al. (2020). Acute Pulmonary Embolism in COVID-19 Patients on CT Angiography and Relationship to D-Dimer Levels. Radiology 201561.
Levi, M., and Poll, T. van der (2017). Coagulation and sepsis. Thromb. Res. 149 : 38–44.
Li, C., Booze, R.M., and Hersh, L.B. (1995). Tissue-specific expression of rat neutral endopeptidase (neprilysin) mRNAs. J. Biol. Chem.270 : 5723–5728.
Li, H., Liu, L., Zhang, D., Xu, J., Dai, H., Tang, N., et al. (2020a). SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet395 : 1517–1520.
Li, H., Liu, S.M., Yu, X.H., Tang, S.L., and Tang, C.K. (2020b). Coronavirus disease 2019 (COVID-19): current status and future perspectives. Int. J. Antimicrob. Agents 55 : 105951.
Li, H., Zuo, J., and Tang, W. (2018). Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases. Front. Pharmacol. 9 :.
Liu, H., Wang, L.L., Zhao, S.J., Kwak-Kim, J., Mor, G., and Liao, A.H. (2020a). Why are pregnant women susceptible to COVID-19? An immunological viewpoint. J. Reprod. Immunol. 139 : 103122.
Liu, T., Zhang, J., Yang, Y., Ma, H., Li, Z., Zhang, J., et al. (2020b). The potential role of IL-6 in monitoring severe case of coronavirus disease 2019. MedRxiv.
Liu, Y., Yang, Y., Zhang, C., Huang, F., Wang, F., Yuan, J., et al. (2020c). Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci. China Life Sci.63 : 364–374.
Luërs, J.C., Klumann, J.P., and Guntinas-Lichius, O. (2020). The COVID-19 pandemic and otolaryngology: What it comes down to? Laryngorhinootologie. 99 : 287–291.
Lyu, J., Miao, T., Dong, J., Cao, R., Li, Y., and Chen, Q. (2020). Reflection on lower rates of COVID-19 in children: Does childhood immunizations offer unexpected protection? Med. Hypotheses 143 : 109842.
Malińska, D., Więckowski, M.R., Michalska, B., Drabik, K., Prill, M., Patalas-Krawczyk, P., et al. (2019). Mitochondria as a possible target for nicotine action. J. Bioenerg. Biomembr. 51 : 259–276.
Mantzarlis, K., Tsolaki, V., and Zakynthinos, E. (2017). Role of Oxidative Stress and Mitochondrial Dysfunction in Sepsis and Potential Therapies. Oxid. Med. Cell. Longev.
Mao, L., Wang, M., Chen, S., He, Q., Chang, J., Hong, C., et al. (2020). Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 77 : 683–690.
Maria, G.U. Di, Bellofiore, S., and Geppetti, P. (1998). Regulation of airway neurogenic inflammation by neutral endopeptidase. Eur. Respir. J.12 : 1454–62.
Marinosci, A., Landis, B.N., and Calmy, A. (2020). Possible link between anosmia and COVID-19: sniffing out the truth. Eur. Arch. Oto-Rhino-Laryngology 277 : 2149–2150.
Martinez, F.J., Calverley, P.M.A., Goehring, U.-M., Brose, M., Fabbri, L.M., and Rabe, K.F. (2015). Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet 385 : 857–866.
McGonagle, D., O’Donnell, J.S., Sharif, K., Emery, P., and Bridgewood, C. (2020). Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol.
Mehra, M.R., Desai, S.S., Ruschitzka, F., and Patel, A.N. (2020). Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet.
Meyer-Hoffert, U. (2009). Neutrophil-derived serine proteases modulate innate immune responses. Front. Biosci. 14 : 3409–3418.
Milara, J., Morcillo, E., Monleon, D., Tenor, H., and Cortijo, J. (2015a). Roflumilast prevents the metabolic effects of bleomycin-induced fibrosis in a murine model. PLoS One 10 : e0133453.
Milara, J., Morell, A., Ballester, B., Sanz, C., Freire, J., Qian, X., et al. (2015b). Roflumilast improves corticosteroid resistance COPD bronchial epithelial cells stimulated with toll like receptor 3 agonist. Respir. Res. 16 : 12.
Milara, J., Peiro, T., Serrano, A., Artigues, E., Aparicio, J., Tenor, H., et al. (2015c). Simvastatin increases the ability of roflumilast N-oxide to inhibit cigarette smoke-induced epithelial to mesenchymal transition in well-differentiated human bronchial epithelial cells in vitro. COPD J. Chronic Obstr. Pulm. Dis. 12 : 327–338.
Molano Franco, D., Arevalo-Rodriguez, I., Roqué I Figuls, M., Montero Oleas, N.G., Nuvials, X., and Zamora, J. (2019). Plasma interleukin-6 concentration for the diagnosis of sepsis in critically ill adults. Cochrane Database Syst. Rev. 4 : CD011811.
Mudter, J., and Neurath, M.F. (2007). Il-6 signaling in inflammatory bowel disease: Pathophysiological role and clinical relevance. Inflamm. Bowel Dis. 13 : 1016–1023.
Muo, I.M., MacDonald, S.D., Madan, R., Park, S.-J., Gharib, A.M., Martinez, P.E., et al. (2019). Early effects of roflumilast on insulin sensitivity in adults with prediabetes and overweight/obesity involve age-associated fat mass loss–results of an exploratory study. Diabetes, Metab. Syndr. Obes. Targets Ther. 12 : 743.
Mustafa, S.B., Gandhi, C.R., Harvey, S.A.K., and Olson, M.S. (1995). Endothelin stimulates platelet-activating factor synthesis by cultured rat kupffer cells. Hepatology 21 : 545–553.
Owa, A.B., and Owa, O.T. (2020). Lopinavir/ritonavir use in Covid-19 infection: is it completely non-beneficial? J. Microbiol. Immunol. Infect.
Pani, A., Lauriola, M., Romandini, A., and Scaglione, F. (2020). Macrolides and viral infections: focus on azithromycin in COVID-19 pathology. Int. J. Antimicrob. Agents 106053.
Patel, B.S., Rahman, M.M., Baehring, G., Xenaki, D., Tang, F.S.-M., Oliver, B.G., et al. (2017). Roflumilast N-oxide in combination with formoterol enhances the antiinflammatory effect of dexamethasone in airway smooth muscle cells. Am. J. Respir. Cell Mol. Biol. 56 : 532–538.
Pham, C.T.N. (2006). Neutrophil serine proteases: Specific regulators of inflammation. Nat. Rev. Immunol. 6 : 541–550.
Press, N.J., and Banner, K.H. (2009). 2 PDE4 Inhibitors - A Review of the Current Field. Prog. Med. Chem. 47 : 37–74.
Rabe, K.F. (2011). Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br. J. Pharmacol. 163 : 53–67.
Rabe, K.F., Watz, H., Baraldo, S., Pedersen, F., Biondini, D., Bagul, N., et al. (2018). Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16-week, randomised, placebo-controlled trial. Lancet Respir. Med. 6 : 827–836.
Raker, V.K., Becker, C., and Steinbrink, K. (2016). The cAMP pathway as therapeutic target in autoimmune and inflammatory diseases. Front. Immunol. 7 : 123.
Rao, G.H.R., and White, J.G. (1982). Platelet activating factor (paf) causes human platelet aggregation through the mechanism of membrane modulation. Prostaglandins, Leukot. Med. 9 : 459–472.
Rao, V.U., Pavlov, A., Klearman, M., Musselman, D., Giles, J.T., Bathon, J.M., et al. (2015). An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy. Arthritis Rheumatol.67 : 372–380.
Rasmo, D. De, Micelli, L., Santeramo, A., Signorile, A., Lattanzio, P., and Papa, S. (2016). CAMP regulates the functional activity, coupling efficiency and structural organization of mammalian FOF1 ATP synthase. Biochim. Biophys. Acta - Bioenerg. 1857 : 350–358.
Reddy, A.T., Lakshmi, S.P., Banno, A., and Reddy, R.C. (2020). Glucocorticoid Receptor α Mediates Roflumilast’s Ability to Restore Dexamethasone Sensitivity in COPD. Int. J. Chron. Obstruct. Pulmon. Dis.15 : 125–134.
Redford, P.S., Murray, P.J., and O’garra, A. (2011). The role of IL-10 in immune regulation during M. tuberculosis infection. Mucosal Immunol.4 : 261–270.
Remy, K.E., Brakenridge, S.C., Francois, B., Daix, T., Deutschman, C.S., Monneret, G., et al. (2020). Immunotherapies for COVID-19: lessons learned from sepsis. Lancet. Respir. Med.
Rhee, C.K., and Kim, D.K. (2020). Role of phosphodiesterase-4 inhibitors in chronic obstructive pulmonary disease. Korean J. Intern. Med.35 : 276–283.
Rosenberg, E.S., Dufort, E.M., Udo, T., Wilberschied, L.A., Kumar, J., Tesoriero, J., et al. (2020). Association of Treatment with Hydroxychloroquine or Azithromycin with In-Hospital Mortality in Patients with COVID-19 in New York State. JAMA - J. Am. Med. Assoc.
Sanz, M.J., Cortijo, J., Taha, M.A., Cerdá-Nicolás, M., Schatton, E., Burgbacher, B., et al. (2007). Roflumilast inhibits leukocyte-endothelial cell interactions, expression of adhesion molecules and microvascular permeability. Br. J. Pharmacol. 152 : 481–492.
Sato, T., Hongu, T., Sakamoto, M., Funakoshi, Y., and Kanaho, Y. (2013). Molecular Mechanisms of N-Formyl-Methionyl-Leucyl-Phenylalanine-Induced Superoxide Generation and Degranulation in Mouse Neutrophils: Phospholipase D Is Dispensable. Mol. Cell. Biol. 33 : 136–145.
Schalkwyk, E. van, Strydom, K., Williams, Z., Venter, L., Leichtl, S., Schmid-Wirlitsch, C., et al. (2005). Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions. J. Allergy Clin. Immunol. 116 : 292–298.
Schouten, M., Wiersinga, W.J., Levi, M., and Poll, T. van der (2008). Inflammation, endothelium, and coagulation in sepsis. J. Leukoc. Biol.83 : 536–545.
Shames, B.D., McIntyre, R.C., Bensard, D.D., Pulido, E.J., Selzman, C.H., Reznikov, L.L., et al. (2001). Suppression of tumor necrosis factor α production by cAMP in human monocytes: Dissociation with mRNA level and independent of interleukin-10. J. Surg. Res. 99 : 187–193.
Shen, L.-F., Lv, X.-D., Chen, W.-Y., Yang, Q., Fang, Z.-X., and Lu, W.-F. (2018). Effect of roflumilast on chronic obstructive pulmonary disease: a systematic review and meta-analysis. Ir. J. Med. Sci.187 : 731–738.
Shimamoto, K., Ura, N., and Iimura, O. (1994). The natriuretic mechanisms of neutral endopeptidase inhibitor in rats. Brazilian J. Med. Biol. Res. Rev. Bras. Pesqui. Medicas e Biol. 27 : 1965–1973.
Silva, S., Amarasena, R., Moorcroft, J., Rajakulenthiran, T., and Singh, R. (2020). Tocilizumab-induced pulmonary fibrosis in a patient with rheumatoid arthritis. Clin. Med. (Northfield. Il). 20 : s57–s57.
Singhal, T. (2020). A Review of Coronavirus Disease-2019 (COVID-19). Indian J. Pediatr. 87 : 281–286.
Song, Y., Liu, P., Shi, X.L., Chu, Y.L., Zhang, J., Xia, J., et al. (2020). SARS-CoV-2 induced diarrhoea as onset symptom in patient with COVID-19. Gut 69 : 1143–1144.
Sont, J.K., Krieken, J.H.J.M. Van, Klink, H.C.J. Van, Roldaan, A.C., Apap, C.R., Willems, L.N.A., et al. (1997). Enhanced Expression of Neutral Endopeptidase (NEP) in Airway Epithelium in Biopsies from Steroid- versus Nonsteroid-treated Patients with Atopic Asthma. Am. J. Respir. Cell Mol. Biol. 16 : 549–556.
Sprague, A.H., and Khalil, R.A. (2009). Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem. Pharmacol.78 : 539–552.
Srivastava, S. (2017). The mitochondrial basis of aging and age-related disorders. Genes (Basel). 8 : 398.
Tabaa, M.M. El, and Tabaa, M.M. El (2020). Targeting Neprilysin (NEP) pathways: A potential new hope to defeat COVID-19 ghost. Biochem. Pharmacol. 114057.
Taghizadeh-Hesary, F., and Akbari, H. (2020). The powerful immune system against powerful COVID-19: A hypothesis. Med. Hypotheses 140 : 109762.
Tamara, A., and Tahapary, D.L. (2020). Obesity as a predictor for a poor prognosis of COVID-19: A systematic review. Diabetes Metab. Syndr. Clin. Res. Rev. 14 : 655–659.
Tay, M.Z., Poh, C.M., Rénia, L., MacAry, P.A., and Ng, L.F.P. (2020). The trinity of COVID-19: immunity, inflammation and intervention. Nat. Rev. Immunol. 20 : 363–374.
Tenor, H., Hatzelmann, A., Church, M.K., Schudt, C., and Shute, J.K. (1996). Effects of theophylline and rolipram on leukotriene C4 (LTC4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects. Br. J. Pharmacol. 118 : 1727–1735.
Togo, S., Liu, X., Wang, X., Sugiura, H., Kamio, K., Kawasaki, S., et al. (2009). PDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGF-β1-stimulated fibroblasts. Am. J. Physiol. - Lung Cell. Mol. Physiol. 296 : L959-69.
Totani, L., Amore, C., Santo, A. Di, Dell’Elba, G., Piccoli, A., Martelli, N., et al. (2016). Roflumilast inhibits leukocyte–platelet interactions and prevents the prothrombotic functions of polymorphonuclear leukocytes and monocytes. J. Thromb. Haemost.14 : 191–204.
Varga, Z., Flammer, A.J., Steiger, P., Haberecker, M., Andermatt, R., Zinkernagel, A.S., et al. (2020). Endothelial cell infection and endotheliitis in COVID-19. Lancet 395 : 1417–1418.
Vishnevetsky, A., and Levy, M. (2020). Rethinking high-risk groups in COVID-19. Mult. Scler. Relat. Disord. 42 : 102139.
Vollert, S., Kaessner, N., Heuser, A., Hanauer, G., Dieckmann, A., Knaack, D., et al. (2012). The glucose-lowering effects of the PDE4 inhibitors roflumilast and roflumilast-N-oxide in db/db mice. Diabetologia 55 : 2779–2788.
Wang, M., Gao, P., Wu, X., Chen, Y., Feng, Y., Yang, Q., et al. (2016). Impaired anti-inflammatory action of glucocorticoid in neutrophil from patients with steroid-resistant asthma. Respir. Res. 17 : 1–9.
Weiss, B., and Hait, W.N. (1977). Selective cyclic nucleotide phosphodiesterase inhibitors as potential therapeutic agents. Annu. Rev. Pharmacol. Toxicol. 17 : 441–477.
Wermuth, P.J., Li, Z., Mendoza, F.A., and Jimenez, S.A. (2016). Stimulation of Transforming Growth Factor-β1-Induced Endothelial-To-Mesenchymal Transition and Tissue Fibrosis by Endothelin-1 (ET-1): A Novel Profibrotic Effect of ET-1. PLoS One11 : e0161988.
Westphal, J.F. (2000). Macrolide - Induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: An update focused on clarithromycin, azithromycin and dirithromycin. Br. J. Clin. Pharmacol.50 : 285–295.
Wick, M.J., Buesing, E.J., Wehling, C.A., Loomis, Z.L., Cool, C.D., Zamora, M.R., et al. (2011). Decreased neprilysin and pulmonary vascular remodeling in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 183 : 330–340.
Wintroub, B.U., Schechter, N.B., Lazarus, G.S., Kaempfer, C.E., and Schwartz, L.B. (1984). Angiotensin I conversion by human and rat chymotryptic proteinases. J. Invest. Dermatol. 83 : 336–339.
Wouters, E.F.M., Bredenbröker, D., Teichmann, P., Brose, M., Rabe, K.F., Fabbri, L.M., et al. (2012). Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus. J. Clin. Endocrinol. Metab.97 : E1720–E1725.
Wu, P., Duan, F., Luo, C., Liu, Q., Qu, X., Liang, L., et al. (2020). Characteristics of Ocular Findings of Patients with Coronavirus Disease 2019 (COVID-19) in Hubei Province, China. JAMA Ophthalmol. 138 : 575–578.
Xiao, Z.M., Sun, L., Liu, Y.M., Zhang, J.J., and Huang, J. (2009). Estrogen regulation of the neprilysin gene through a hormone-responsive element. J. Mol. Neurosci. 39 : 22–26.
Xiong, Y., Liu, Y., Cao, L., Wang, D., Guo, M., Jiang, A., et al. (2020). Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerg. Microbes Infect. 9 : 761–770.
Yang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., et al. (2020). Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir. Med. 8 : 475–481.
Yao, M., Nguyen, T.V. V., Rosario, E.R., Ramsden, M., and Pike, C.J. (2008). Androgens regulate neprilysin expression: Role in reducing β-amyloid levels. J. Neurochem. 105 : 2477–2488.
Zhang, H., Penninger, J.M., Li, Y., Zhong, N., and Slutsky, A.S. (2020a). Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 46 : 586–590.
Zhang, Y., Geng, X., Tan, Y., Li, Q., Xu, C., Xu, J., et al. (2020b). New understanding of the damage of SARS-CoV-2 infection outside the respiratory system. Biomed. Pharmacother. 127 : 110195.
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., et al. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet395 : 1054–1062.
Ziebuhr, J. (2005). The coronavirus replicase. Curr. Top. Microbiol. Immunol. 287 : 57–94.
Zuo, Y., Zuo, M., Yalavarthi, S., Gockman, K., Madison, J.A., Shi, H., et al. Neutrophil extracellular traps and thrombosis in COVID-19. MedRxiv.
Zyl-Smit, R.N. van, Richards, G., and Leone, F.T. (2020). Tobacco smoking and COVID-19 infection. Lancet Respir. Med. 1451–1454.
Table 1: Multiple pharmacological properties of roflumilast.